A Pilot Study of the Safety, Efficacy, and Effects on Functional Imaging of the Combination of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma.

Trial Profile

A Pilot Study of the Safety, Efficacy, and Effects on Functional Imaging of the Combination of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2013

At a glance

  • Drugs Girentuximab (Primary) ; Sunitinib (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 27 Feb 2013 Last checked against ClinicalTrials.gov record.
    • 01 Sep 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 21 Jun 2011 Planned end date changed from 1 Jun 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top